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Abstract
Introduction: Gastric	cancer	during	pregnancy	is	extremely	rare	and	data	on	optimal	
treatment	and	possible	chemotherapeutic	regimens	are	scarce.	The	aim	of	this	study	
is	 to	 describe	 the	 obstetric	 and	maternal	 outcome	of	women	with	 gastric	 cancer	
during	pregnancy	and	review	the	literature	on	antenatal	chemotherapy	for	gastric	
cancer.
Material and methods: Treatment	 and	 outcome	 of	 patients	 registered	 in	 the	
International	 Network	 on	 Cancer,	 Infertility	 and	 Pregnancy	 database	with	 gastric	
cancer	diagnosed	during	pregnancy	were	analyzed.
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1  | INTRODUC TION
Gastric	cancer	is	one	of	the	most	common	cancers,	with	very	specific	
geographical,	 ethnic	 and	 socioeconomic	 differences	 in	 incidence.	
GLOBACAN	 (Global	 cancer	 observatory,	 WHO)	 data	 estimated	
about	1	million	new	patients	in	2018.1	More	than	70%	of	gastric	can‐
cer	cases	occur	in	developing	countries	and	most	patients	come	from	
Eastern	Asia.	Known	risk	factors	for	gastric	cancer	include	age,	smok‐
ing,	ethnicity	and	geography,	history	of	gastric	ulcer,	and	immunosup‐
pressive	disease.	Exposure	 to	Helicobacter pylori	 plays	a	 role	 in	 the	
development	 of	 non‐cardiac	 cancer,	whereas	 gastroesophageal	 re‐
flux	disease	and	obesity	are	risk	factors	especially	for	cardiac	cancer.	
Typically	gastric	cancer	has	a	male	predominance	and	is	diagnosed	at	
a	median	age	of	70	years,	whereas	only	1%	of	patients	are	<34	years	
at	diagnosis.2	Pregnancy‐associated	gastric	cancer,	defined	as	a	diag‐
nosis	of	gastric	cancer	during	pregnancy	or	up	to	1	year	after	delivery,	
is	estimated	to	complicate	0.026%‐0.1%	of	all	pregnancies.3
Gastric	 cancer	 is	 staged	 according	 to	 the	 American	 Joint	
Committee	on	Cancer/Union	for	International	Cancer	Control	TNM	
staging	system,	based	upon	tumor	size	(T),	lymph	node	invasion	(N),	
and	 metastatic	 disease	 (M).	 Early	 gastric	 cancer	 is	 limited	 to	 the	
mucosa	 or	 submucosa	 (T1),	 whereas	 the	 tumor	 is	 assumed	 to	 be	
clinically	 localized	once	 the	muscular	 layer	 (T2)	 is	 invaded.	Stage	 I	
gastric	cancer	 is	 limited	to	the	stomach,	whereas	 in	stage	II	 lymph	
nodes	are	affected	or	the	tumor	spreads	to	the	subserosa	or	serosa	
(T3‐4aN0).	In	stage	III	the	tumor	invades	both	(sub)serosa	and	lymph	
nodes,	in	stage	IV	the	tumor	has	spread	to	the	adjacent	organs	with	
lymph	 nodes	 affected	 or	 distant	 organs.	 The	 stage	 distribution	 in	
the	general	population	is	21.6%	for	stage	I,	22.3%	for	stage	II,	44.0%	
for	 stage	 III,	 and	12.1%	 for	 stage	 IV.4	Pregnant	women	are	at	 risk	
for	delayed	diagnosis	of	gastric	cancer	because	symptoms	may	be	
regarded	as	gestational	 features	and	because	of	 the	 reluctance	 to	
perform	invasive	diagnostic	procedures	such	as	gastroscopy.5	As	a	
result,	 gastric	 cancer	 is	 often	diagnosed	 in	more	 advanced	 cancer	
stages.	Gastric	cancer	that	invades	through	the	submucosa	stage	II	
or	higher	with	no	evidence	of	distant	metastases,	or	locally	advanced	
inoperable	disease	can	be	treated	with	curative	intent	by	surgical	re‐
section	and	perioperative	chemotherapy.6 In locally advanced unre‐
sectable	or	metastatic	gastric	cancer,	surgery	is	not	a	feasible	option	
and	palliative	chemotherapy	can	be	considered.	Standard	cytotoxic	
treatment	for	primary	gastric	cancer	consists	of	a	platinum‐fluoro‐
pyrimidine‐based	 regimen,	 such	as	FOLFOX	 (5‐fluorouracil	 [5‐FU],	
leucovorin	and	oxaliplatin),	CAPOX	(capecitabine,	oxaliplatin),	ECF/
ECC	(epirubicin,	cisplatin,	5‐FU/capecitabine)	or	EOX	(epirubicin,	ox‐
aliplatin,	 capecitabin).	 Trastuzumab	 combinations	may	 be	 adminis‐
tered	in	case	of	HER2‐overexpressing	gastric	cancers.	Alternatively,	
taxane‐based	schedules	may	be	applied,	such	as	FLOT	(5‐FU,	leucov‐
orin,	oxaliplatin,	docetaxel).
Various	 chemotherapy	 regimens	 are	 feasible	during	pregnancy	
without	 an	 increased	 risk	 of	 congenital	 malformations	 if	 adminis‐
tered	after	the	first	trimester.7	More	pregnant	women	with	cancer	
are	 now	 treated	with	 chemotherapy	 so	 as	 to	 not	 delay	 treatment	
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Results: In	 total,	 13	women	with	 gastric	 cancer	 during	pregnancy	were	 registered	
between	2002	and	2018.	Median	gestational	age	at	diagnosis	was	22	weeks	(range	
6‐30	weeks).	Twelve	women	were	diagnosed	with	advanced	disease	and	died	within	
2	years	after	pregnancy,	most	within	6	months.	In	total,	8	out	of	10	live	births	ended	in	
a	preterm	delivery	because	of	preeclampsia,	maternal	deterioration,	or	therapy	plan‐
ning.	Two	out	of	6	women	who	initiated	chemotherapy	during	pregnancy	delivered	at	
term.	Two	neonates	prenatally	exposed	to	chemotherapy	were	growth	restricted	and	
1	of	them	developed	a	systemic	infection	with	brain	abscess	after	preterm	delivery	
for	preeclampsia	2	weeks	after	chemotherapy.	No	malformations	were	reported.
Conclusions: The	prognosis	of	gastric	cancer	during	pregnancy	is	poor,	mainly	due	to	
advanced	disease	at	diagnosis,	emphasizing	the	need	for	early	diagnosis.	Antenatal	
chemotherapy	can	be	considered	to	reach	fetal	maturity,	taking	possible	complica‐
tions	such	as	growth	restriction,	preterm	delivery,	and	hematopoietic	suppression	at	
birth	into	account.
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Key message
Early	 recognition	of	 symptoms	of	 gastric	 cancer	 in	 preg‐
nant	women	allows	curative	treatment	but	is	hampered	by	
low	incidence	of	complaints	in	early	cancer	and	the	over‐
lapping	symptoms	with	pregnancy.	Chemotherapy	during	
pregnancy	might	 be	 considered	 if	 parents	 are	 counseled	
for	neonatal	risks.
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while	avoiding	preterm	birth	or	pregnancy	termination	as	much	as	
possible.7	 To	 date,	 the	 relative	 safety	 of	 antenatal	 chemotherapy	
is	mainly	demonstrated	 for	 treatments	used	 in	breast	and	cervical	
cancer,	 and	 lymphomas,	but	experience	with	gastric	 cancer	 is	 lim‐
ited.7	Most	large	case	series	on	gastric	cancer	during	pregnancy	do	
not	report	on	the	use	and	consequences	of	cytotoxic	treatment	and	
include	only	Asian	patients.3,8,9	However,	biological	behavior	and	re‐
sponse	to	treatment	may	show	geographic	differences.10	Therefore,	
we	selected	all	women	with	a	diagnosis	and/or	treatment	of	gastric	
cancer	 during	 pregnancy	 from	 the	 international	 “cancer	 in	 preg‐
nancy”	 International	Network	on	Cancer,	 Infertility	and	Pregnancy	
(INCIP)	registry	(www.cance	rinpr	egnan	cy.org).	We	conducted	a	re‐
view	of	cases	where	chemotherapy	was	initiated	during	pregnancy	
and	assessed	neonatal	outcome	in	this	population.
2  | MATERIAL AND METHODS
All	women	diagnosed	with	primary	or	recurrent	gastric	cancer	dur‐
ing	pregnancy	were	selected	from	the	database	of	the	International	
Cancer	 in	 Pregnancy	 registration	 study	 (Clinicaltrials.gov,	 number	
NTC00330447).	 The	 registry	 contains	 retrospectively,	 and	 since	
2005	 prospectively,	 collected	 oncological	 and	 obstetrical	 data	 of	
women	diagnosed	with	any	pregnancy‐associated	malignancy.	The	
registered	cases	are	reported	by	physicians,	 INCIP	members,	with	
a	special	interest	in	cancer	in	young	women.	Currently	the	registry	
contains	 2059	women	with	 a	 cancer	 diagnosis	 during	 pregnancy,	
registered	by	European	 (Belgium	25%,	 the	Netherlands	21%,	 Italy	
13%,	 Czech	 Republic	 6%)	 and	 non‐European	 (Philadelphia,	 USA	
13%,	 Russia	 8%,	 Mexico	 6%)	 centers.	 For	 the	 present	 study,	 pa‐
tient	 data	on	 treatment	 and	obstetrical	 outcomes	were	 collected.	
Referring	 physicians	 were	 contacted	 to	 complete	 missing	 data.	
Small‐for‐gestational‐age	(SGA)	was	defined	as	a	birthweight	below	
the	 10th	 centile,	 and	 centiles	were	 corrected	 for	 gestational	 age,	
sex,	maternal	height,	maternal	weight,	ethnicity,	and	parity	accord‐
ing	to	the	calculator	from	the	Gestation	Network	(www.gesta	tion.
net;	 v8.0.2,	 2018)	 Preterm	 delivery	 was	 defined	 as	 birth	 before	
37	weeks	of	gestation.
In	addition,	we	performed	a	narrative	 review	and	searched	for	
case	reports	and	case	series,	as	well	as	articles	on	treatment	options	
for	gastric	cancer	during	pregnancy,	published	in	the	English	litera‐
ture.	Articles	were	identified	by	a	PUBMED	search	with	the	follow‐
ing	MESH	terms:	“pregnancy”,	“gastric	cancer”,	and	“chemotherapy”	
and	variations	thereof.	For	statistics,	we	used	descriptive	analysis.	
Comparative	analysis	was	not	performed	because	of	the	small	num‐
ber	of	patients.
2.1 | Ethics approval
The	international	registration	study	“Cancer	in	Pregnancy”	was	ap‐
proved	by	the	Ethics	Committee	of	University	Hospitals	of	Leuven	
(B322201421061)	23	May	2014	and	participating	centers	according	
to	local	policies.
3  | RESULTS
3.1 | Patient and tumor characteristics
In	 total,	 13	 women	 diagnosed	 with	 primary	 or	 recurrent	 gastric	
cancer	 during	 pregnancy	 were	 retrieved	 from	 the	 registry	 (see	
Supplementary	material,	Table	S1).	They	were	diagnosed	between	
March	2002	and	November	2017	in	6	countries	(The	Netherlands,	
n	=	5;	USA,	n	=	3;	Belgium,	n	=	2;	Czech	Republic,	n	=	1;	Italy,	n	=	1;	
and	France,	n	=	1).	One	woman	with	a	diagnosis	of	gastric	carcinoma	
in	situ	treated	with	surgery	and	in	remission	for	1	year	before	preg‐
nancy was excluded.
All	women,	 except	1,	were	diagnosed	with	 advanced	or	meta‐
static	disease	 (12/13,	92.3%).	Patient	demographics	 are	described	
in	 Table	 1.	Median	maternal	 age	 at	 diagnosis	was	32	 years	 (range	
26‐39	 years),	 median	 gestational	 age	 at	 diagnosis	 was	 21	 weeks	
(range	 6‐30	weeks).	Most	 patients	were	 diagnosed	with	 a	 diffuse	
type	(signet	ring	cell	carcinoma)	of	gastric	cancer.	One	woman	was	
found	to	be	pregnant	on	the	computed	tomography	scan	that	was	
performed	during	trastuzumab	maintenance	therapy.	This	case	high‐
lights	the	 importance	of	pregnancy	testing	because	young	women	
can	 still	 be	 fertile	 despite	 amenorrhea	 secondary	 to	 cancer	 treat‐
ment.	 Most	 women	 (9/13,	 69%)	 presented	 with	 gastrointestinal	
symptoms	 (nausea	 and	 vomiting	 [5/13,	 39%],	 diarrhea	 [1/13,	 8%],	
distended	 abdomen	 [3/13,	 23%]).	 One	 woman	 presented	 with	 a	
palpable	 cervical	 adenopathy.	 Because	 the	 origin	 of	 the	 primary	
tumor	was	initially	uncertain,	she	was	initiated	with	carboplatin	and	
paclitaxel	 during	pregnancy	 and	 switched	postpartum	 to	 cisplatin,	
doxorubicin	 and	 trastuzumab	when	 a	 computed	 tomography	 scan	
revealed	a	gastric	tumor.	Another	woman	presented	with	vertebral	
pain	 caused	 by	 bone	metastasis.	 Two	 had	 ascites,	 in	 combination	
with	liver	metastasis	or	peritoneal	metastasis.	Five	women	were	di‐
agnosed	with	ovarian	Krukenberg	tumors.
3.2 | Surgical and chemotherapeutic management 
during pregnancy
One	 woman	 with	 stage	 II	 cancer	 started	 with	 chemotherapy	 at	
23	weeks	of	gestation	 followed	by	curative	gastrectomy	after	de‐
livery.	In	total,	10	women	had	ongoing	pregnancies	with	inoperable	
gastric	 cancer	 and	 in	5	women	chemotherapy	was	 initiated	 in	 the	
second	 trimester	 of	 pregnancy.	 The	 chemotherapeutic	 regimens	
used	during	pregnancy	were:	5‐FU,	FOLFOX	and	carboplatin/pacli‐
taxel.	One	woman	underwent	surgery	with	a	curative	intent	but	was	
diagnosed	 with	 intestinal	 metastasis	 perioperatively	 and	 initiated	
palliative	chemotherapy	after	elective	cesarean	section	at	32	weeks.	
Four	patients	received	no	definitive	surgical	or	cytotoxic	treatment	
during	pregnancy	aside	from	adnexectomies.
3.3 | Obstetrical outcome
As	 described	 in	 Table	 1,	 there	was	 1	 termination	 of	 pregnancy,	 2	
pregnancy	 losses	 and	 10	 live	 births.	 One	 woman	 pregnant	 with	
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twins	opted	 for	a	 termination	of	pregnancy	at	23	weeks	of	gesta‐
tion	because	of	metastatic	disease.	One	woman	died	from	the	dis‐
ease	2	weeks	after	diagnosis	at	22	weeks	of	gestation.	One	woman	
miscarried	at	19	weeks	of	gestation	following	an	exploratory	lapa‐
rotomy	and	adnexectomy.	Three	women	underwent	an	emergency	
cesarean	section	for	preeclampsia	between	27	and	33	weeks	of	ges‐
tation,	and	another	was	delivered	at	29	weeks	of	gestation	by	cesar‐
ean	section	because	of	clinical	maternal	deterioration.	Four	women	
had	 an	 iatrogenic	 preterm	 delivery	 for	 therapy	 planning.	 Only	 2	
women	delivered	at	term,	both	received	chemotherapy	during	preg‐
nancy	and	had	an	elective	cesarean	section	for	maternal	reasons.
3.4 | Maternal outcome
All	 mothers	 with	 stage	 IV	 gastric	 cancer	 were	 deceased	 within	
24	months	after	pregnancy,	 the	majority	within	6	months.	Overall	 
1‐year	survival	was	31%.	The	only	woman	 in	remission	12	months	
after	 diagnosis	 had	 stage	 II	 gastric	 cancer	 and	 was	 treated	 with	
chemotherapy	during	pregnancy	followed	by	gastrectomy.
3.5 | Outcome of the children
In	total	10	pregnancies	ended	 in	a	 live	birth.	All	6	neonates	pre‐
natally	 exposed	 to	 chemotherapy	were	 born	without	 congenital	
malformations	and	all,	except	1	with	a	birthweight	of	2950	g	and	
term	delivery,	were	admitted	to	the	neonatal	 intensive	care	unit,	
mostly	for	prematurity	(4/5	or	80%).	One	infant	born	at	term	was	
admitted	for	neonatal	abstinence	syndrome	due	to	maternal	use	
of	methadone.	 Two	 neonates	 prenatally	 exposed	 to	 chemother‐
apy,	 to	6	cycles	FOLFOX	and	3	cycles	carboplatin/paclitaxel,	 re‐
spectively,	 (2/6	 or	 33%)	were	 SGA	 at	 birth.	 The	 4	 non‐exposed	
neonates	 were	 admitted	 to	 the	 neonatal	 intensive	 care	 unit	 for	
prematurity	and	2	of	them	where	SGA	(2/4	or	50%).	The	neonatal	
period	of	1	child	born	at	32	weeks	of	gestation,	2	weeks	after	the	
last	 administration	 of	 carboplatin,	was	 complicated	 by	 a	Bacillus 
cereus	 infection	 with	 a	 cerebral	 abscess.	 This	 was	 treated	 with	
antibiotics,	but	 the	neonate	had	residual	cerebral	palsy,	epilepsy	
and	 hemianopia.	 Despite	 these	 symptoms	 requiring	 intensive	
physiotherapy,	 the	 child	 was	 doing	 well	 in	 cognitive	 develop‐
ment	 at	 15	months,	 3	 years	 and	 6	 years	 of	 follow	 up	 according	
to	standardized	and	clinical	measures	of	neurocognitive	functions.	
One	child	born	at	34	weeks	of	gestation	was	cognitively	assessed	
at	18	months	of	age	and	had	appropriate	cognitive	development	
when	corrected	for	his	prematurity	at	birth.	Available	middle‐	to	
long‐term	 follow	up	of	4	children	 that	 are	 included	 in	 the	 INCIP	
study	is	shown	in	Table	2.
3.6 | Results of narrative literature review
The	largest	review	to	date	of	137	Japanese	women	with	pregnancy‐
associated	 gastric	 cancer	was	 published	 in	 2009;	 one‐third	 of	 the	
women	with	reported	timing	of	delivery	were	diagnosed	with	gastric	
cancer	 postnatally.3	 The	 authors	 identified	 that	 92.5%	 of	 the	 pa‐
tients	had	advanced	stage	gastric	cancer	and	the	diffuse	type	was	
the	 most	 common	 histological	 diagnosis.	 Maternal	 outcome	 was	
poor	with	1‐	and	2‐year	survival	rate	of	18.3%	and	15.1%.	A	review	
TA B L E  1  Patient	characteristics
 
Present 
cases, n (%)
Total	number	of	cases 13
Age	(years),	median	(range) 31.7 
(26.9‐39.9)
Gestational	age	at	diagnosis	(wk),a 	median	(range) 22	(6‐30)
Gestational	age	at	delivery	(wk),	median	(range) 32(19‐39)
History	of	smoking 4	(31%)
Histopathology
	Diffuse	type 12	(100%)
	Signet	ring	cell 8	(67%)
	Intestinal	type 0
	Unknown 1
Disease	stage	at	diagnosis
	Stage	II 1	(8%)
	Stage	IV 12	(92%)
Treatment	during	pregnancy
	Chemotherapy 6	(46%)
	Surgery	with	curative	intent 1	(8%)
	Exploratory	surgery	(palliative) 3	(23%)
Deferral	of	treatment	until	after	delivery 3	(23%)
Obstetrical	outcome
	Termination	of	pregnancy 1	(8%)
	Late	miscarriage/IUD 2	(15%)
	Live	birth 10	(77%)
	<28	wk 1
	<34	wk 5
	<37	wk 2
	Term 2
Complications
	Preeclampsia 3	(23%)
	Spontaneous	preterm	delivery 1	(8%)
	Low	birthweight	(<P10)a 4	(44%)
Mode	of	delivery
	Vaginal	delivery 2	(20%)
	Cesarean	section 8	(80%)
Placental	metastasis 0
Maternal	outcome
	Deceased	during	pregnancy 1	(8%)
	Alive	in	3	mo 9	(69%)
	Alive	in	6	mo 7	(54%)
	Alive	in	12	mo	or	more 4	(31%)
Abbreviation:	IUD,	intrauterine	death	(deceased	with	mother).
Excluded	1	patient	with	recurrent	gastric	cancer	during	pregnancy.
a1	case	birthweight	unknown.	
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of	31	cases	(42%	postpartum	diagnosis)	from	western	academic	jour‐
nals	between	1969	and	1999	and	a	case	series	of	65	Asian	women	
(35%	postpartum	diagnosis)	published	in	2014	had	similar	findings.8,9
In	the	literature	we	identified	5	women	receiving	a	5‐FU‐based	
regimen	for	advanced	gastric	cancer	during	pregnancy,	with	re‐as‐
suring	fetal	outcomes.11‐13	Details	are	summarized	 in	Table	3.	One	
woman	received	paclitaxel	and	S1	(tegafur	[=prodrug	of	active	sub‐
stance	5‐FU],	gimeracil,	oteracil)	and	delivered	a	growth	restricted	
baby	at	34	weeks	of	gestation.14	Nishie	et	al	summarized	3	additional	
Japanese	cases	with	re‐assuring	neonatal	outcome	after	prenatal	ex‐
posure	to	S1	and	taxanes	(cases	not	included	as	reported	in	Japanese	
language).14
4  | DISCUSSION
In	 this	 case	 series	 the	 obstetrical	 and	maternal	 outcomes	 of	 13	
women	 with	 a	 diagnosis	 of	 primary	 or	 recurrent	 gastric	 cancer	
during	pregnancy	are	 reported.	Most	women	were	diagnosed	at	
an	 advanced	 stage	with	 a	 diffuse	 type	 adenocarcinoma,	 includ‐
ing	 8	women	with	 signet	 ring	 cell	 carcinoma.	 Larger	 case	 series	
had	 similar	 findings,	 but	 none	 of	 these	 studies	 reported	 on	 the	
use	 of	 chemotherapy	 during	 pregnancy	 or	 neonatal	 outcome	 in	
detail	and	most	included	a	large	percentage	of	women	diagnosed	
postnatally.3,8,9
Five‐year	 survival	 in	 young	 (≤40	 years)	 patients	 is	 47.6%	 in	
general,	but	is	highly	dependent	on	tumor	stage	(range	83.3%	for	
stage	I	and	0%	for	stages	III	and	IV).15	Young	patients	are	reported	
to	have	lower	overall	survival	compared	with	patients	>40	years	
of	 age	 if	 curative	 resection	 is	not	 achieved.15	Furthermore,	 in	 a	
retrospective	 analysis	 of	 clinical‐pathological	 features	 and	 out‐
come	of	4722	non‐pregnant	patients,	female	sex	was	significantly	
associated	with	a	younger	age	at	diagnosis,	poorly	differentiated	
adenocarcinoma	 and	 signet	 ring	 cell	 carcinoma.16	 Due	 to	 these	
features,	overall	survival	was	poorer	for	female	than	for	male	pa‐
tients,	 especially	 among	 patients	 younger	 than	 45	 years	 of	 age	
with	 advanced	 disease.	 The	 histological	 features	 of	 the	 gastric	
cancer	in	pregnant	patients	are	similar	to	those	reported	in	non‐
pregnant	 female	 patients.	 Nevertheless,	 gastric	 cancer	 during	
pregnancy	 has	 a	 poor	 prognosis	 with	 reported	 median	 overall	
survival	of	7	months	and	3‐year	overall	survival	of	23.3%.	One‐
year	overall	survival	in	this	series	was	31%	(4/13	alive	12	months	
after	 diagnosis).To	 evaluate	 the	 effect	 of	 pregnancy	 on	 gastric	
cancer,	 Lee	 et	 al	 compared	 15	 pregnant	 patients	 with	 53	 age‐
matched	 non‐pregnant	 patients.5	 During	 gestation,	 93%	 of	 pa‐
tients	were	diagnosed	with	advanced	 stage	gastric	 cancer,	60%	
of	tumors	were	unresectable	and	3‐year	survival	rate	was	23.3%.	
Significant	differences	between	both	groups	were	found	regard‐
ing	the	tumor	stage,	but	 in	multivariate	analysis,	pregnancy	was	
not	 found	 to	 be	 an	 independent	 risk	 factor.	 It	 is	 unknown	 if	 a	
delay	 in	diagnosis	due	to	pregnancy	explained	this	difference	 in	
tumor	stage.	A	more	recent	study	that	compared	overall	survival	
of	20	patients	with	pregnancy‐associated	gastric	cancer	with	39	
age‐	 and	 stage‐matched	 non‐pregnant	 females	 concluded	 that	
advanced	stage	and	tumor	location	but	not	pregnancy	status	are	
poor	prognostic	factors.17
Estrogen	receptors	(ER)	are	found	in	about	20%‐30%	of	human	
gastric	cancers,	mainly	 in	the	poorly	differentiated	type.8	A	recent	
meta‐analysis	suggested	that	the	tumoral	expression	of	ERα	might	
indicate	 poor	 survival	 and	 the	 absence	 of	 ERβ	 is	 associated	 with	
lymph	 node	metastasis.18	 However,	 the	 clinical	 significance	 of	 ER	
and	(if	there	is)	estrogen‐dependent	tumor	growth	in	gastric	cancer	
is	still	unclear.
There	 is	 no	 evidence	 of	 severe	 adverse	 neonatal	 outcome	 or	
increased	 risk	 of	 congenital	malformations	 if	 regimens	 are	 admin‐
istered	 after	 fetal	 organogenesis	 (occurring	 2‐8	 weeks	 after	 con‐
ception)	while	avoiding	preterm	delivery.7,19	The	degree	of	placental	
transfer	of	drugs	depends	on	molecular	weight,	lipophilicity,	ioniza‐
tion	 at	 physiological	 pH	 and	 plasma	 protein	 binding,	 besides	 drug	
dose	and	gestational	age	at	exposure.	Also,	 interaction	with	active	
drug	 transporters,	 like	 p‐glycoprotein	 and	 BCRP	 (Breast	 Cancer	
Resistance	Protein)	might	 affect	 the	 transfer	 rate.	 Preclinical	 data	
and	the	limited	clinical	data	of	individual	drugs	used	in	the	treatment	
of	gastric	cancer	during	pregnancy	are	summarized	 in	Table	4.19‐29 
Albeit,	in	clinical	practice,	most	chemotherapeutic	agents	are	given	
in	combination	regimens	with	co‐medication,	which	might	also	influ‐
ence	the	placental	transfer	through	drug	interactions.
Most	pregnant	patients	presented	with	extensive	intra‐abdom‐
inal	disease	that	theoretically	might	provoke	spontaneous	preterm	
contractions.	 Interestingly	 all	 preterm	deliveries,	 except	 1,	were	
iatrogenic	 for	 oncological	 or	 obstetrical	 reasons.	 Four	 out	 of	 10	
infants	were	SGA	and	this	is	of	special	interest	because	perinatal	
morbidity	 and	 mortality,	 and	 cardiovascular	 and	 metabolic	 dis‐
eases,	are	more	frequently	seen	in	SGA	children	than	in	children	
of	average	weight	(according	to	gestational	age)	at	birth.30	SGA	in	
this	population	might	be	explained	by	the	poor	maternal	general	
and	nutritional	status	inherent	to	gastric	cancer.	In	addition,	2	of	
these	children	were	prenatally	exposed	to	chemotherapy,	which	is	
also	reported	to	be	associated	with	SGA.7	In	this	series	3	women	
developed	preeclampsia,	possibly	explained	by	the	relatively	high	
maternal	age	(diagnoses	at	the	age	of	27,	37	and	39	for	the	3	cases,	
respectively).
Current	 recommendations	 for	 the	 management	 of	 pregnant	
women	 with	 a	 diagnosis	 of	 gastric	 cancer	 is	 based	 on	 available	
case series.3,5,8	Treatment	options	depend	on	gestational	age	and	
cancer	stage.	 If	possible,	 the	best	oncologic	management	for	 the	
mother	should	be	aimed	for.	An	individualized	management	plan	is	
required,	always	taking	patient's	perspective	into	account.	In	case	
of	primary	resectable	disease,	curative	treatment	should	be	aimed	
for	 with	 or	 without	 perioperative	 chemotherapy,	 depending	 on	
stage.	Depending	on	 the	surgeon's	expertise	and	 the	gestational	
age,	a	laparoscopic	approach	is	feasible.	In	late	pregnancy,	preterm	
delivery	can	be	considered	as	the	gravid	uterus	and	maternal	gen‐
eral	condition	can	complicate	surgery;	however,	 for	optimal	 fetal	
outcome,	 term	 delivery	 should	 always	 be	 aimed	 for	 if	 possible.	
When	perioperative	chemotherapy	 is	 indicated,	 cytotoxic	agents	
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may	be	administered	during	pregnancy	(from	the	second	trimester	
onwards)	so	as	to	not	delay	treatment	and	to	enhance	fetal	matu‐
rity.	In	patients	diagnosed	with	advanced	stages	of	disease,	where	
no	cure	is	possible,	immediate	onset	of	systemic	(palliative)	treat‐
ment	might	be	 indicated	to	treat	symptoms	and	to	enhance	fetal	
maturity	 if	 there	 is	 a	wish	 to	 continue	 pregnancy.	 In	 early	 preg‐
nancy,	and	especially	in	advanced	cases,	termination	of	pregnancy	
can	also	be	 considered.	Available	 case	 reports	on	 chemotherapy	
during	 pregnancy	 for	 gastric	 and	 colorectal	 cancer	 suggest	 that	
5‐FU‐based	 regimens	 (i.e.	 FOLFOX)	 are	 feasible.11‐14,26 In gen‐
eral,	 the	 use	 of	 cytotoxic	 drugs	 can	 only	 be	 justified	 if	 the	 risks	
of	both	mother	and	child	are	balanced	and	the	benefits	for	mater‐
nal	outcome	outweigh	 the	possible	adverse	effects	on	 the	child.	
Studies	on	the	short‐term	neurocognitive	development	of	children	
reveal	that	preterm	delivery	rather	than	prenatal	exposure	to	can‐
cer	 treatment	 is	 responsible	 for	 impaired	 cognitive	 outcome.19 
However,	 long‐term	 outcome	 of	 children	 prenatally	 exposed	 to	
chemotherapy	remains	under	 investigation	and	further	 follow	up	
of	these	children	is	indispensable.
Although	this	series	on	western	patients	is	small,	we	report	on	
the	use	of	chemotherapy	for	gastric	cancer	during	pregnancy	and	
the	 neonatal	 outcome	 in	 detail	 including	 follow	 up.	 Continuous	
prospective	registration	of	cases	will	facilitate	future	patient	coun‐
seling.	 International	collaboration	 is	welcomed	 in	order	 to	collect	
data	 in	 larger	 numbers	 to	 improve	 treatment	 approach	 during	
pregnancy.
5  | CONCLUSION
In	 summary,	 gastric	 cancer	 during	 pregnancy	 is	 a	 rare	 diagnosis.	
Women	present	 usually	 in	 advanced	 stage	 and	 have	 a	 poor	 prog‐
nosis.	Early	recognition	of	symptoms	is	 indispensable	for	diagnosis	
at	a	curative	stage.	In	pregnant	women	with	persistent	gastrointes‐
tinal	symptoms	that	cannot	be	explained	by	pregnancy	alone	there	
should	be	a	low	threshold	for	further	diagnostic	procedures.	While	
balancing	maternal	 and	 fetal	 risks,	 the	 initiation	 of	 chemotherapy	
during	pregnancy	may	be	considered	in	order	to	reach	fetal	maturity.
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